Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
N/A
A retrospective study of de-identified (to preserve patient privacy) patien...
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
PHASE3
A study to compare the safety and efficacy of an aromatase inhibitor in com...
Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer
PHASE2
This prospective, response-adapted phase II study evaluates the efficacy an...
Status
Recruiting
Location
The First Affiliated Hospital of Nanjing Medical University
The Performance of Patient Support Program in Early Stage Breast Cancer
N/A
The purpose of this study is to compare the 1-year adherence to upfront adj...
Status
Completed
Location
Research Site
Start Date
2008-09
Trial ID
NCT00769080
A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors
PHASE2
Metastatic breast cancer (MBC) remains an incurable disease and despite an ...
Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy
PHASE3
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone th...